Literature DB >> 28039096

Assessment of Cognitive, Emotional, and Motor Domains in Patients with Diffuse Gliomas Using the National Institutes of Health Toolbox Battery.

Stefan Lang1, Magalie Cadeaux2, Micheal Opoku-Darko2, Ismael Gaxiola-Valdez3, Lisa A Partlo2, Bradley G Goodyear4, Paolo Federico5, John Kelly6.   

Abstract

OBJECTIVE: Patients with brain tumors are known to have deficits in cognitive, motor, and emotional domains. Comprehensive evaluation of the patient with brain tumor includes taking into account all these domains at baseline and throughout treatment. Standard neuropsychological assessment methods, however, are lengthy, expensive, and often are variable. The authors appraised the feasibility of using a brief, inexpensive, comprehensive, and standardized neuropsychological battery, the National Institutes of Health (NIH) Toolbox, to assess these domains in patients with diffuse glioma.
METHODS: Eighteen patients were recruited and completed the NIH Toolbox Cognitive Battery, 2 motor tests (Grip Strength and Grooved Pegboard), and the NIH Toolbox Emotional Battery. Fully corrected T scores are reported, as well as composite scores of fluid and crystallized cognition. Follow-up cognitive (n = 13) and motor assessment (n = 12) were performed at 1 month after surgery.
RESULTS: The total time to complete the battery was approximately 60 minutes. A total of 78% of patients demonstrated significant impairment on one or more cognitive test, whereas 37% had impaired fluid cognition. Crystallized and overall composite cognitive scores were relatively intact, with 16% of patients showing significant impairment. A total of 22% of patients had impaired strength in the left hand, and 22% had impaired dexterity in both hands. In addition, 50% of patients showed impairment in one or more emotional domain. At 1 month after surgery, a significant decrease in crystallized cognition was observed.
CONCLUSIONS: The NIH Toolbox represents a feasible alternative to current neuropsychological batteries in the assessment of neurosurgical patients. It can be administered quickly, inexpensively, and will give the neurosurgical community a common currency when reporting neuropsychological results.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain tumor; Cognition; Glioma; Neuropsychology

Mesh:

Year:  2016        PMID: 28039096     DOI: 10.1016/j.wneu.2016.12.061

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Psychometric Properties of the NIH Toolbox Cognition Battery in Healthy Older Adults: Reliability, Validity, and Agreement with Standard Neuropsychological Tests.

Authors:  Emmi P Scott; Anne Sorrell; Andreana Benitez
Journal:  J Int Neuropsychol Soc       Date:  2019-07-01       Impact factor: 2.892

Review 2.  A systematic review of cognitive function in patients with glioblastoma undergoing surgery.

Authors:  Rohitashwa Sinha; Jade Marie Stephenson; Stephen John Price
Journal:  Neurooncol Pract       Date:  2019-04-23

3.  Monitoring neurocognitive functioning in childhood cancer survivors: evaluation of CogState computerized assessment and the Behavior Rating Inventory of Executive Function (BRIEF).

Authors:  Lyn M Balsamo; Hannah-Rose Mitchell; Wilhelmenia Ross; Catherine Metayer; Kristina K Hardy; Nina S Kadan-Lottick
Journal:  BMC Psychol       Date:  2019-05-02

4.  Preoperative Transcranial Direct Current Stimulation in Glioma Patients: A Proof of Concept Pilot Study.

Authors:  Stefan Lang; Liu Shi Gan; Cael McLennan; Adam Kirton; Oury Monchi; John J P Kelly
Journal:  Front Neurol       Date:  2020-11-19       Impact factor: 4.003

5.  T2 FLAIR Hyperintensity Volume Is Associated With Cognitive Function and Quality of Life in Clinically Stable Patients With Lower Grade Gliomas.

Authors:  Tracy L Luks; Javier E Villanueva-Meyer; Christina Weyer-Jamora; Karin Gehring; Angela Jakary; Shawn L Hervey-Jumper; Steve E Braunstein; Paige M Bracci; Melissa S Brie; Ellen M Smith; Susan M Chang; Jennie W Taylor
Journal:  Front Neurol       Date:  2022-01-28       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.